EASI-75 interpretation from a patient perspective - a phase 2b post-hoc analysis of dupilumab in adults with moderate-to-severe atopic dermatitis

被引：0
|
作者：
Poulin, Y. [1 ,2 ]
Tyring, S. [3 ,4 ]
Kimura, T. [5 ]
Andria, M. [5 ]
Ghorayeb, E. [6 ]
Eckert, L. [7 ]
Chao, J. [5 ]
机构：
[1] Ctr Rech Dermatol Quebec Metropolitain, Quebec City, PQ, Canada
[2] Univ Laval, Quebec City, PQ, Canada
[3] Univ Texas Hlth Sci Ctr Houston, Ctr Clin Studies, Houston, TX 77030 USA
[4] Univ Texas Hlth Sci Ctr Houston, Dept Dermatol, Houston, TX 77030 USA
[5] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[6] Sanofi, Cambridge, MA USA
[7] Sanofi, Chilly Mazarin, France
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2017年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [1] Interpretation of EASI-75 from a patient perspective - a post-hoc analysis from a phase 2b trial of dupilumab in adults with moderate-to-severe atopic dermatitis
    Poulin, Y.
    Tyring, S.
    Kimura, T.
    Andria, M.
    Ghorayeb, E.
    Eckert, L.
    Chao, J.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 142 - 142
  • [2] The effect of dupilumab on biomarkers in a randomized phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis
    Hamilton, J.
    Hamon, S.
    Simpson, E.
    Chaudhry, U.
    Swanson, B.
    Zhang, R.
    Graham, N.
    Pirozzi, G.
    Ardeleanu, M.
    Rizova, E.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S224 - S224
  • [3] Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults
    Simpson, Eric L.
    Bieber, Thomas
    Eckert, Laurent
    Wu, Richard
    Ardeleanu, Marius
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Mastey, Vera
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (03) : 491 - 498
  • [4] Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus
    Silverberg, Jonathan, I
    Pinter, Andreas
    Pulka, Grazyna
    Poulin, Yves
    Bouaziz, Jean-David
    Wollenberg, Andreas
    Murrell, Dedee F.
    Alexis, Andrew
    Lindsey, Lisa
    Ahmad, Faiz
    Piketty, Christophe
    Clucas, Alan
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (01) : 173 - 182
  • [5] The patient burden of atopic dermatitis: insights from a dupilumab phase 2 clinical trial in adults with moderate-to-severe disease
    Mastey, V.
    Simpson, E.
    Bieber, T.
    Eckert, L.
    Wu, R.
    Ardeleanu, M.
    Graham, N.
    Pirozzi, G.
    Sutherland, E. R.
    [J]. EXPERIMENTAL DERMATOLOGY, 2014, 23 : 4 - 4
  • [6] Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
    Paller, Amy S.
    Bansal, Ashish
    Simpson, Eric L.
    Boguniewicz, Mark
    Blauvelt, Andrew
    Siegfried, Elaine C.
    Guttman-Yassky, Emma
    Hultsch, Thomas
    Chen, Zhen
    Mina-Osorio, Paola
    Lu, Yufang
    Rossi, Ana B.
    He, Xinyi
    Kamal, Mohamed
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ruddy, Marcella
    Eckert, Laurent
    Gadkari, Abhijit
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (01) : 119 - 131
  • [7] Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
    Amy S. Paller
    Ashish Bansal
    Eric L. Simpson
    Mark Boguniewicz
    Andrew Blauvelt
    Elaine C. Siegfried
    Emma Guttman-Yassky
    Thomas Hultsch
    Zhen Chen
    Paola Mina-Osorio
    Yufang Lu
    Ana B. Rossi
    Xinyi He
    Mohamed Kamal
    Neil M. H. Graham
    Gianluca Pirozzi
    Marcella Ruddy
    Laurent Eckert
    Abhijit Gadkari
    [J]. American Journal of Clinical Dermatology, 2020, 21 : 119 - 131
  • [8] Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis and a history of nonsteroidal immunosuppressant use: a post hoc analysis of the phase III CAFE trial
    Bouaziz, J. -D.
    Ogg, G.
    de Bruin-Weller, M.
    Bieber, T.
    Irvine, A.
    Shumel, B.
    Msihid, J.
    Rossi, A. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 : 66 - 67
  • [9] Dupilumab Improves Patient-Reported Outcomes (PROs) in a Phase 2 Study in Adults with Moderate-to-Severe Atopic Dermatitis
    Simpson, Eric
    Worm, Margitta
    Soong, Weily
    Blauvelt, Andrew
    Eckert, Laurent
    Wu, Richard
    Ardeleanu, Marius
    Graham, Neil
    Pirozzi, Gianluca
    Sutherland, E. Rand
    Mastey, Vera
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB167 - AB167
  • [10] Achieving an itch-free state with Upadacitinib: a post-hoc analysis of data from the Phase 2b randomized, doubleblind, placebo-controlled trial in moderate-to-severe atopic dermatitis
    Silverberg, J.
    Reich, K.
    Calimlim, B., III
    Gu, Y.
    Hu, X.
    Teixera, H.
    Guttman-Yassky, E.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 37 - 37
12345